Activity of synthetic peptides against Chlamydia by Donati, Manuela et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Activity of synthetic peptides against Chlamydia
Donati, Manuela; Cenacchi, Giovanna; Biondi, Roberta; Papa, Valentina; Borel, Nicole; Nepita,
Edoardo Vecchio; Magnino, Simone; Pasquinelli, Gianandrea; Levi, Aurora; Franco, Octavio L
Abstract: The in vitro activity of six synthetic peptides against 36 strains of Chlamydia from different
origins was investigated. Clavanin MO proved to be the most active peptide, reducing the inclusion
number of all Chlamydia strains from 8 different species tested by ￿50% at 10 ￿g.ml-1. Mastoparan L
showed an equal activity against C. trachomatis, C. pneumoniae, C. suis and C. muridarum, but did not
exert any inhibitory effect against C. psittaci, C. pecorum, C. abortus and C. avium even at 80 ￿g.ml-1.
These data suggest that clavanin MO could be a promising compound in the prevention and treatment
of chlamydial infections.
DOI: https://doi.org/10.1002/bip.23032
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-138217
Originally published at:
Donati, Manuela; Cenacchi, Giovanna; Biondi, Roberta; Papa, Valentina; Borel, Nicole; Nepita, Edoardo
Vecchio; Magnino, Simone; Pasquinelli, Gianandrea; Levi, Aurora; Franco, Octavio L (2017). Activity of
synthetic peptides against Chlamydia. Biopolymers, 108(6):e23032.
DOI: https://doi.org/10.1002/bip.23032
 Activity of synthetic peptides against Chlamydia  
Manuela Donati,a Giovanna Cenacchi,b Roberta Biondi,a Valentina Papa,b Nicole Borel,c Edoardo 
Vecchio Nepita,a Simone Magnino,d  Gianandrea Pasquinelli,e Aurora Levi,a and Octavio L. 
Francof,g  
DIMES, Microbiology, University of Bologna, 40138 Bologna, Italya; DIBINEM, Pathology, 
University of Bologna, 40138 Bologna, Italyb; Institute of Veterinary Pathology, Vetsuisse Faculty, 
University of Zurich, CH-8057 Zurich, Switzerland;c IZSLER, National Reference laboratory for 
Animal Chlamydioses, 27100 Pavia, Italyd; DIMES, Pathology, University of Bologna, 40138 
Bologna, Italye; Centre of Proteomics and Biochemistry, Catholic University of Brasilia, Brasilia, 
DF, Brazilf, S-Inova Biotech, Pos-Graduação em Biotecnologia, Universidade Catolica Dom Bosco, 
Campo Grande, MS, Brazilg. 
 Correspondence 
Octavio L. Franco, Centre of Proteomics and Biochemistry, Catholic University of Brasilia, 
Brasilia, DF, Brazil. Tel.: +55 61 34487220; fax: +55 61 33474797 
e-mail: ocfranco@gmail.com  
 Keywords 
Chlamydia/peptides/antimicrobial/immunofluorescence 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/bip.23032
This article is protected by copyright. All rights reserved.
2 
 
 
ABSTRACT 
The in vitro activity of six synthetic peptides against 36 strains of Chlamydia from different origins 
was investigated. Clavanin MO proved to be the most active peptide, reducing the inclusion number 
of all Chlamydia strains from 8 different species tested by ≥50% at 10 µg.ml-1. Mastoparan L 
showed an equal activity against C. trachomatis, C. pneumoniae, C. suis and C. muridarum, but did 
not exert any inhibitory effect against C. psittaci, C. pecorum, C. abortus and C. avium even at 80 
µg.ml-1. These data suggest that clavanin MO could be a promising compound in the prevention and 
treatment of chlamydial infections. 
 
Running title 
In vitro sensitivity of Chlamydia to synthetic peptides 
 
INTRODUCTION 
Chlamydiae are obligate intracellular Gram-negative bacteria belonging to the family of 
Chlamydiaceae, genus Chlamydia, including eleven species that affect a wide range of vertebral 
hosts, causing significant diseases both in humans and economically important domestic animals 
such as sheep, poultry and a variety of wildlife.1 The three Chlamydia species infecting humans are 
represented by C. trachomatis, responsible for urogenital diseases and associated with neonatal 
conjunctivitis and pneumonitis, C. pneumoniae, causing respiratory infections and associated with 
cardiovascular diseases, and C. psittaci, transmitted occasionally from infected birds to humans, 
causing psittacosis. Chronic or persistent infections have been reported for these Chlamydia species. 
In particular, persistent C. trachomatis infections can cause long-term sequelae including pelvic 
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inflammatory disease and tubal factor infertility.2 The Chlamydia species infecting other animals 
are represented by C. psittaci (in birds and mammals), C. suis (in pigs), C. felis (in cats), C. 
pecorum and C. abortus (in sheep, goats, cattle, pigs), C. caviae (in guinea pigs), C. muridarum (in 
mice), and the two recently proposed species of C. avium (in pigeons and parrots) and C. gallinacea 
(in chickens).3 Chlamydiae infecting animals can cause a variety of diseases ranging from mild 
infections like conjunctivitis and enteritis to more serious disorders such as pneumonia, 
polyarthritis, pericarditis, encephalitis and reproductive problems (especially in sows and boars).4 
Although C. psittaci and C. abortus zoonotic potential is well known, the zoonotic transmission of 
the other species is still unclear and has to be investigated. Both human and animal chlamydial 
infections are primarily treated with tetracycline or its derivatives and macrolides.5 Despite the in 
vitro antimicrobial activity of these drugs against C. trachomatis and most of the other Chlamydia 
species, there are reports of tetracycline treatment failure in humans.6 In addition, a stable 
tetracycline-resistance associated with tet(C) genomic islands integrated into the chlamydial 
chromosome has been described for C. suis strains isolated from pigs,7 as well as a tetracycline 
resistance expressed in vitro by C. trachomatis following co-culture with tetracycline-resistant C. 
suis strains.8 
In this context, the formulation of synthetic peptides with antimicrobial activity has become 
extremely attractive. Several studies demonstrated the in vitro antimicrobial activity of synthetic 
peptides against various antibiotic-resistant Gram-positive and Gram-negative bacteria. Some 
studies evaluated the in vitro activity of natural and synthetic host defence peptides against 
Chlamydia spp., demonstrating protegrins and α-helical peptides to be the most active peptides and 
C. trachomatis the most sensitive among Chlamydia species tested.9 Our recent investigation 
showed substantial in vitro activity of cathelicidin SMAP-29, in comparison with five other 
cathelicidins, against C. trachomatis and C. pneumoniae.10  On the other hand, the potent SMAP-29 
antimicrobial activity is associated with toxicity towards mammalian cells.  
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Infections caused by antibiotic-resistant bacteria such as the group called ESKAPE (Enterococcus 
faecium, Staphilococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacter spp.) have contributed to increases in patient mortality. Due to these 
facts, the formulation of synthetic peptides with improved solubility and antimicrobial activity and 
lower toxic effects towards mammalian cells has become extremely attractive.11 The good activity 
of synthetic peptides, such as the wasp-generated peptide mastoparan,12 clavanins (cationic α-
helical peptides from the marine tunicate Styela clava),13 and Pa-MAP (an alanine-rich peptide with 
hydrophobic amino acid residues from the polar fish Pleuronectes americanus) against some Gram-
positive and Gram-negative bacteria has been reported.14,15 
Since the anti-chlamydial activity of these peptides has not been tested so far, we evaluated the in 
vitro activity of multiple synthetic peptides against Chlamydia. This evaluation aims to assess a 
possible therapeutic use in clinically unresolved C. trachomatis infections treated with traditional 
drugs or to prevent or treat C. suis infections caused by tetracycline-resistant strains on pig farms. In 
particular, in the present study we tested the in vitro activity of peptides such as mastoparans, 
clavanins and polyalanines against Chlamydia strains belonging to eight of the eleven known 
Chlamydia species. We selected the Chlamydia species pathogens for humans, represented by C. 
trachomatis and C. pneumoniae, and the species with a zoonotic potential or causing infections with 
implications for farming and veterinary industries, such as C. psittaci, C. abortus, C. suis and C. 
pecorum. Additionally, we examined the mouse pneumonia agent C. muridarum, widely used to 
model diseases caused by C. trachomatis due to their high relatedness, and finally the recently 
classified and still little known C. avium.  
As it is well known, chlamydiae present a unique developmental growth cycle characterized by an 
infectious elementary body (EB) that enters the cells and, within a cytoplasmic inclusion, is 
transformed in a non-infectious reticulate body (RB) which multiplies by binary fission for about 
21-24 h. At that time, the RBs reorganize into EBs that exit the infected cells 36-48 h post-infection 
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and invade new cells. In cell monolayers in vitro, the number of cells showing cytoplasmic 
inclusions, containing colonies of chlamydiae, represents the degree of infectivity or infecting 
forming units (IFU). 
In order to determine whether the peptides, including different forms of mastoparans and 
clavanins,16, 17  were able to reduce in vitro chlamydial infectivity acting directly on Chlamydia EBs 
or on the cells previously infected by Chlamydia, EBs purified from the eight Chlamydia species, as 
well as Chlamydia infected cells, were treated with the synthetic peptides and then any reduction in 
chlamydial infectivity was determined. Subsequently, a transmission electron microscopy study was 
performed on Chlamydia infectious EBs that were untreated and on others after their treatment with 
the active peptides, to better investigate the effects of the peptides on these microorganisms, by 
detecting possible ultra-structural EBs alterations, such as the appearance of vacuolar degeneration 
and disrupted membranes.  
 
MATERIAL AND METHODS 
Peptide synthesis 
    The in vitro anti-chlamydial activity of the synthetic peptides mastoparan L (ML) (NH2-
INLKALAALAKKIL-COOH) originally, isolated from wasp venom, and its analogue MO17 
(MMO) (under protection), clavanin A (C) (NH2-VFQFLGKIIHHVGNFVHGFSHVF-COOH)18 
originally purified from the sea tunicate Styela clava, and its modified version named clavanin MO 
(CMO) (NH2-FLPIIVFQFLGKIIHHVGNFVHGFSHVF-COOH),16 and Pa-MAP 2 (NH2-
LKAAAAAAKLAAKAAKAALKAAAAAAKL-COOH)19  and 1.9 (NH2-
LAAKLTKAATKLTAALTKLAAALTAAAT-COOH),20 which are peptides derived from the 
polyalanine peptide from the Antarctic fish Pleuronectes americanus, was investigated. All peptides 
were synthesized by Peptides 2.0 (Chantilly, VA, USA) by solid-phase with the N-9-
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fluorenylmethyloxycarbonyl (Fmoc) technique. Peptides were further purified by high-performance 
liquid chromatography (HPLC) and the identity of each peptide was confirmed by MALDI-ToF MS 
(Bruker, Germany) (data not shown). Peptide purity used in biologic assays was > 95%. 
Chlamydia strains tested 
The strains we tested included 23 human and 13 animal Chlamydia strains, belonging to eight 
different Chlamydia species. C. trachomatis comprised 18 strains represented by nine isolates from 
urethral swabs of male patients with non gonococcal urethritis admitted to S. Orsola Hospital 
(Bologna, Italy) and typed as D, E, F, G, H and K serovars and nine USA reference strains (Ic Cal-8 
serovar D, Bour serovar E, Ic Cal-3 serovar F, 392-F serovar G, 580 serovar H, 870 serovar I, UW-
36 serovar J, UW-31 serovar K and 434 serovar L2), kindly provided by Prof. Julius Schachter 
(University of California, San Francisco, USA). C. pneumoniae included 5 strains comprising the 
two reference strains IOL-207 (originally isolated in 1967 in London from an Iranian child with 
trachoma) and CM-1 (the clinical isolate ATCC VR-1360), provided by the Centers for Disease 
Control and Prevention, Atlanta, GA, USA, and three Italian strains isolated from patients with 
pneumonia admitted to S. Orsola Hospital (Bologna). The 13 animal Chlamydia strains included: 
the reference strain Nigg of C. muridarum, kindly provided by Dr. Orietta Finco (Novartis, Siena, 
Italy) the reference avian strain 6BC (USA) of C. psittaci (Prof. J. Schachter, University of 
California, San Francisco, USA), 4 pigeon isolates of C. psittaci, 2 C. abortus strains isolated from 
sheep with reproductive disorders, 2 C. pecorum isolates from cattle with encephalitis, 1 pigeon 
isolate of the recently classified C. avium species, 2 C. suis strains isolated in the Vetswiss Faculty 
(University of Zurich, Switzerland) from pigs with conjunctivitis. C. psittaci, C. abortus, C. 
pecorum and C. avium strains were isolated in the Diagnostic Section, Zooprophylactic Institute 
(IZSLER, Pavia, Italy). 
In vitro activity of synthetic peptides against Chlamydia  
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Chlamydia strains were cultivated in LLC-MK2 cells21 (a continuous cell line derived from Rhesus 
monkey kidney tissue) grown at 37°C, in the presence of 5% CO2, in 24-well plates containing a 
glass coverslip (diameter, 12 mm) at the bottom. The cell growth medium was Eagle’s minimum 
essential medium (EMEM) supplemented with 10% heat inactivated fetal calf serum (FCS), 10 
mg.l-1 gentamicin, 10 mg.l-1 vancomycin and containing 2mM glutamine and 1.7 mg.l-1 glucose. 
The infectious EBs were purified by use of a sucrose gradient,22 resuspended in 0.2 M sucrose-
phosphate-glutamic acid (SPG), and frozen in 0.1 ml aliquots at -80°C. For each peptide a stock 
solution of 1g.l-1 in phosphate-buffered saline, pH 7.4 was prepared and subsequently stored at -
80°C. Chlamydial infectivity, or inclusion-forming units (IFU), was determined by counting the 
number of fluorescent cells with cytoplasmic inclusions that appeared after the cells were infected 
by chlamydiae. A peptide is considered active if it is able to reduce by ≥50% the number of cells 
with inclusions in comparison to the cells infected by the same amount of chlamydiae but not 
treated with the peptide. In order to calculate the lowest peptide concentration capable of prevent 
the detection of more than 50% of the chlamydial inclusions compared with untreated controls, each 
peptide was twofold diluted from 80 to 1.25 µg.ml-1 in phosphate-buffered saline (PBS) pH 7.4 in a 
volume of 100 µl in polypropylene tubes. Subsequently, 100 µl of 103 IFU per ml of purified EBs in 
SPG were added to an equal volume of each peptide concentration and incubated for 2 h at room 
temperature. Untreated EBs were used as a control. The 200 µl mixture was added to 800 µl of 
chlamydial growth medium represented by EMEM supplemented with 10% FCS, glucose (5mg.l-1), 
cycloheximide (1 mg.l-1) and inoculated onto LLC-MK2 cells grown in 24-well plates containing a 
glass coverslip (diameter, 12 mm) at the bottom. After a centrifugation at 800×g for 1.5 h at 33°C, 
the plates were incubated at 37°C for 48-72 h in the presence of 5% CO2, after removing the 
medium and adding chlamydial growth medium. In parallel, in order to evaluate an activity of 
peptides on cells infected by chlamydiae, we infected cell monolayers with an inoculum of 
Chlamydia strains that yielded 1×102 IFU per ml; after a centrifugation at 800×g for 1.5 h at 33°C, 
we removed the medium from the infected monolayers and added the synthetic peptides diluted 
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twofold from 80 to 1.25 µg.ml-1 in chlamydial growth medium. The cultures were then fixed and 
stained for the detection of chlamydial inclusions by using a fluorescein-conjugated monoclonal 
antibody against Chlamydia genus-specific antigen (Meridian, Cincinnati, OH, USA). 
Subsequently, the number of cells containing fluorescent Chlamydia inclusions was determined 
using a Zeiss UV microscope. All tests were run in triplicate and each datum reported is the mean 
of the data obtained in three repeated experiments.  
Transmission electron microscopy analysis 
The transmission electron microscopy investigation was performed by using 100 µl of purified C. 
pneumoniae EBs suspended in SPG medium and treated for 2 h at room temperature with 8 µl of 
peptides (stock solution), in order to achieve a final peptide concentration of 80 µg.ml-1. The 
peptide-treated and the untreated EBs were pelleted by ultra-centrifugation for 30 min at 4°C. After 
removal of the supernatant, the peptide-treated and the untreated EBs were fixed in 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2-7.4 at 4°C for at least 4 h, washed in 0.1 M 
cacodylate buffer pH 7.2 and post-fixed in 1% OsO4 in 0.1 M cacodylate buffer pH 7.2 for 1 h at 
4°C. Then, pellets were dehydrated in graded ethanol and embedded in Araldite (Serva). Thin and 
ultrathin sections were obtained using an ultra-microtome (Ultracut). The ultrathin sections were 
counterstained with uranyl acetate and lead citrate and examined by a Zeiss EM109 transmission 
electron microscope.  
 
RESULTS 
In comparison with untreated controls, CMO reduced by ≥50% the inclusion numbers of all 36 
Chlamydia strains at a concentration of 10 µg.ml-1. In particular, the infectivity reduction of C. 
trachomatis, C. pneumoniae, C. psittaci, C. suis, C. muridarum, C. pecorum, C. abortus and C. 
avium strains tested was greater than 50% after their treatment with CMO at 10 µg.ml-1 and greater 
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than 90% at a CMO concentration of  80 µg.ml-1 (data not shown).  Otherwise, ML at 10 µg.ml-1 
was able to reduce by ≥50% the infectivity of strains belonging to only four out of the eight 
Chlamydia species tested: C. trachomatis, C. pneumoniae, C. suis, and C. muridarum. The 
cytoplasmic inclusion number of the strains belonging to these Chlamydia species was reduced by ≥ 
90% at a CMO concentration of 80 µg.ml-1 (data not shown). ML did not exert any inhibitory effect 
on the remaining strains tested, belonging to C. psittaci, C. pecorum, C. abortus and C. avium 
species, even at 80 µg.ml-1. The remaining four out of the six peptides tested (MMO, C, Pa-MAP 2 
and Pa-MAP 1.9) were ineffective against the EBs purified from all 36 Chlamydia strains tested, 
even at 80 µg. ml-1 (Table 1). Furthermore, the addition of the six peptides after infecting the cells 
with EBs of the eight Chlamydia species investigated, did not significantly reduce chlamydial 
infectivity, in comparison to the infected cells not treated with the peptides. In particular, these 
peptides were not able to reduce by ≥50% the chlamydial IFU, even at the concentration of 80 
µg.ml-1. Moreover, CMO and ML peptides, active when incubated with chlamydial EBs before the 
subsequent cell infection, did not inhibit chlamydial growth when added to already-infected cell 
monolayers (Table 2). 
Interestingly, none of the six peptides showed any cytotoxic effect after LLC-MK2 uninfected cells 
were treated for 48-72 h with a concentration of each peptide ranging from 80 to 1.25 µg.ml-1. In 
addition, evident morphological alterations were not visible under the UV microscope in the 
peptide-treated cells, even at a peptide concentration of 80 µg.ml-1.  
The transmission electron microscope investigation on C. pneumoniae EBs treated with CMO and 
ML peptides proved to be active in vitro against this Chlamydia species, showing a probable 
membrane vacuolar degeneration particularly evident in CMO-treated EBs in comparison to the 
integrity and the regular shape of the peptide-untreated EBs. C. pneumoniae EBs, treated with ML, 
showed only occasionally a vacuolar degeneration and membrane alterations (Figure 1). In both 
cases, peptides lead to the presence of cellular fragments, mainly observed in the left side of Figures 
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1B and 1C, probably yielded by the presence of antimicrobial peptides utilized. Otherwise, these 
fragments were not observed in untreated samples (Figure 1A).   
 
DISCUSSION 
Chlamydia infections play a major role in both human and animal diseases. In particular, 
irreversible infertility can result from persistent and unresolved C. trachomatis infections, and 
significant economic and agricultural damage can be caused by Chlamydia infections on pig, cattle 
and poultry farms.1 The availability of active drugs against Chlamydia is therefore useful both for 
the treatment of human and animal infections and for the prophylactic antibiotic treatment in animal 
herds. 
Although a therapeutic effect on chlamydiae can be expected from tetracyclines, macrolides and 
quinolones, some cases of human and animal infections with therapeutic failure or infections in 
swine caused by tetracycline-resistant strains, containing the tetracycline-resistant gene, may 
occur.23 Tetracyclines are indeed widely used in veterinary medicine because they are relatively 
inexpensive and present a broad-spectrum activity. 
In this regard, it is important to have molecules available with efficient antimicrobial activity 
against chlamydiae. In several organisms, antimicrobial peptides, as components of the innate 
immune system, represent the first barrier against microbial infections and can interact with 
different targets such as membranes, cell wall, nucleic acid or cytosolic proteins.24 The mechanism 
of action of antimicrobial peptides is primarily related to the global positive charge of most of them, 
leading to interaction with anionic microorganism membranes, leading to the formation of pores, or 
acting as detergents, among other membrane level mechanisms of action.12  
With regard to the antimicrobial peptides used in the present study, it is known that CMO interacts 
with bacterial lipid bilayers resulting in drastic changes in membrane morphology,25 Mastoparan 
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analogues (with an extra positive charge at the C-terminal) cause disruption of bacterial 
membrane12 and Pa-MAP antimicrobial activity can be attributed mostly to its hydrophobic 
interactions.14 CMO has demonstrated antimicrobial activity against S. aureus and K. pneumoniae,25 
with mastoparan analogues working against Acinetobacter baumannii12 and Pa-MAP against S. 
aureus and E. coli.26 
As concerns the in vitro activity of synthetic peptides against Chlamydia spp., our previous study 
demonstrated the ability of the cathelicidin SMAP-29 to reduce by ≥ 50% the inclusion numbers of 
all the C. trachomatis and C. pneumoniae strains tested at 10 µg ml-1, while none of the animal 
Chlamydia strains tested were sensitive to SMAP-2910.  
In the present study, two out of the six peptides that were tested in vitro proved to be active against 
chlamydiae. CMO demonstrated a high and broad spectrum activity since the peptide, in contrast 
with the original clavanin A at the concentration of 10 µg.ml-1, reduced by ≥50% the infectivity of 
all strains tested, belonging to eight Chlamydia species, including the new and recently identified C. 
avium species. Otherwise, the eight Chlamydia species tested showed different susceptibility to ML, 
with C. trachomatis, C. pneumoniae, C. muridarum, and C. suis being susceptible at 10 µg.ml-1 and 
C. psittaci, C. pecorum, C. abortus, C. avium not sensitive to this peptide, even at 80 µg.ml-1. 
Similar data were observed by Silva et al.,16 in a study that showed the improvement of activity 
caused by addition of a short tag, engineered at the N-terminus of original clavanin. Moreover, 
similar effects were obtained with another modification added to ML (unpublished data). Last but 
not least, the two polyalanine peptides Pa-MAP 2 and Pa-MAP 1.9 here studied were, surprisingly, 
not active against Chlamydia, as observed  against other  bacterial pathogens.19, 20  
The inhibitory activity showed by ML against only a few chlamydial species tested, in comparison 
to CMO, which is active against all the Chlamydia species investigated, suggests that variations in 
the chlamydial membrane composition can influence the susceptibility to the peptides. 
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It is noteworthy that the anti-chlamydial activities of CMO and ML were not related to their ability 
to enter Chlamydia-infected cells and subsequently to inhibit intracellular chlamydial growth, but 
were due instead to a specific activity directed against infectious chlamydial forms. 
Our observations by transmission electron microscopy analysis suggest that CMO can act at the 
level of the bacterial membrane, since disrupted membranes were observed in Chlamydia EBs 
treated with the peptide. These observations are in accordance with the finding that clavanins and 
mastoparans interact with lipid bilayers, resulting in drastic changes in membrane morphology, 
previously reported in literature.27,28 Another interesting point is that clavanins do not shown a 
typical membrane disturbance activity. This was observed by Silva et al.18, which showed that intra-
cellular effects could also be detected, suggesting multiple targets. Similar data was also here 
observed. In Figure 1B and C it is clearly observed that several cells did not present membrane 
disturbance, indication that not only membranes are affected by peptides here utilized. Furthermore, 
the activity of CMO we observed on Chlamydia EBs in the transmission electron microscopy 
analysis is similar to that showed in our previous ultra-structural study on Chlamydia EBs treated 
with the cathelicidin SMAP-29, causing the loss of integrity of most particles9.  
However, in this respect we can point out that, although cathelicidins and other host defense 
peptides have been shown to be effective in some in vivo studies, their effective dose is very close 
to the toxic dose.29 In addition, they are cytotoxic to mammalian cells. The lack of CMO 
cytotoxicity highlighted in our investigation could be similar to the findings of a previous study 
where clavanin A showed no cytotoxic activity against mammalian cells and in acute toxicity 
tests13.  
The transmission electron microscopy analysis suggests also for ML a permeabilization effect on 
the Chlamydia EB membrane, even though it is less pronounced compared to that of CMO: this 
observation is in agreement with the well-known ability of mastoparan to interact with the 
phospholipid constituents of animal and bacterial cell membranes.30 
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The availability of active anti-chlamydial peptides could be very useful if we focus on some 
observations: the reported tetracycline treatment failure in some C. trachomatis human infections, 
the in vitro evidence of the adaptability of C. trachomatis to evolve to antibiotic resistance and the 
widespread prevalence of C. suis tetracycline-resistant strains on pig farms. In addition, the impact 
on human and animal health of the selection for antimicrobial-resistant Chlamydia strains in the 
animal reservoir is not sufficiently known. Further studies are needed to consider the peptides we 
tested in the present study as potential and promising compounds in the therapy of chlamydial 
infections with treatment failure. Furthermore, if these peptides will be active in vivo at the 
concentrations that have been shown to be active in vitro, in the absence of toxic effects, they could 
be used in humans as well as in animals to prevent chlamydial infections. 
 
CONCLUSION 
We showed a high and specific in vitro activity of the two synthetic peptides CMO and ML, 
belonging to clavanins and mastoparans, respectively, against the infectious forms (EBs) of some 
Chlamydia species relevant in human and animal diseases, in the absence of toxic effect against 
mammalian cells. We highlighted also a broader anti-chlamydial activity of CMO in comparison to 
ML. 
The transmission electron microscopy analysis showed a loss of integrity of the peptide-treated 
EBs, particularly evident in CMO-treated EBs. 
These findings, combined with the already proven in vitro and in vivo activity of CMO and ML 
against both Gram-positive and Gram-negative bacteria, suggest that these peptides and primarily 
CMO could be attractive candidates for the treatment of chlamydial unresolved or persistent human 
infections as well as for the prevention and treatment of chlamydial long-term infections on 
livestock farms, particularly pig farms where tetracycline resistant C. suis strains circulate. 
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Figure 1 - Transmission electron micrographs of Chlamydia pneumoniae EBs. (a) Untreated EBs; (b) EBs 
treated with CMO; (c) EBs treated with ML.                                         185 × 52mm (300 × 300 DPI)  
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Table 1. Activity of clavanins (CMO and C), mastoparans (ML and MMO), and  polyalanins 
Pa-Map 2 and 1.9 peptides against EBs of different Chlamydia spp. 
_______________________________________________________________________________                                              
                                          Peptide concentration (µg.ml-1) reducing chlamydial inclusions by ≥50% 
 
Strains (n) CMO C ML MMO Pa-Map 2  Pa-Map 1.9 
C. trachomatis (18) 10 >80 10 >80 >80 >80 
C. pneumoniae (5) 10 >80 10 >80 >80 >80 
C. psittaci (5) 10 >80 >80 >80 >80 >80 
C. suis (2) 10 >80 10 >80 >80 >80 
C. muridarum (1) 10 >80 10 >80 >80 >80 
C. pecorum (2) 10 >80 >80 >80 >80 >80 
C. abortus (2) 10 >80 >80 >80 >80 >80 
C. avium (1) 10 >80 >80 >80 >80 >80 
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Table 2. Activity of clavanins (CMO and C), mastoparans (ML and MMO), and  polyalanins 
Pa-Map 2 and 1.9 peptides against cells infected with EBs of different Chlamydia spp. 
_______________________________________________________________________________                                              
                                          Peptide concentration (µg.ml-1) reducing chlamydial inclusions by ≥50% 
 
Strains (n) CMO C ML MMO Pa-Map 2  Pa-Map 1.9 
C. trachomatis (18) >80 >80 >80 >80 >80 >80 
C. pneumoniae (5) >80 >80 >80 >80 >80 >80 
C. psittaci (5) >80 >80 >80 >80 >80 >80 
C. suis (2) >80 >80 >80 >80 >80 >80 
C. muridarum (1) >80 >80 >80 >80 >80 >80 
C. pecorum (2) >80 >80 >80 >80 >80 >80 
C. abortus (2) >80 >80 >80 >80 >80 >80 
C. avium (1) >80 >80 >80 >80 >80 >80 
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